About ACCUITIS, INCORPORATED
Accuitis is a late pre-clinical stage pharmaceutical company focused on developing therapeutics that protect and restore healthy cellular function in neurodegenerative diseases such as Alzheimer's, Parkinson's, and methamphetamine addiction. Their lead compound, AN-018, has been validated in extensive preclinical research.
Development of therapeutics for neurodegenerative diseasesPreclinical research and development of disease-modifying therapeuticsRestoration of mitochondrial SIRT3 expressionFocus on age-related and metabolic diseases
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to ACCUITIS, INCORPORATED right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.